Viropharma — Investor Presentation (January 2010)
21 slides from Viropharma's investor presentation, Jan 11, 2010
Slide 1: ViroPharma Incorporated: Delivering Innovative Treatments for Life-threatening Diseases
ViroPharma Incorporated Delivering Innovative Treatments for Life-threatening Diseases ViroPharma Incorporated Delivering Innovative Treatments for Life-threatening Diseases Exhibit 99.2
Slide 2: Slide 2
Slide 3: Forward-looking statements
This presentation contains certain forward-looking statements that involve risks and uncertainties including statements regarding our financial guidance for 2009 and 2010, our ability to continue to execute a successful launch of Cinryze, our ability to achieve peak year sales projections, our abili
Slide 4: ViroPharma
VIROPHARMA
Slide 5: Slide 5
Slide 6: ViroPharma
ViRORHARMA
Slide 7: A Prophylactic Option
A Prophylactic Option • Only C1-INH indicated for routine prophylaxis • Addresses the underlying cause of the disease • Proven to reduce frequency, number and severity of HAE attacks • Self-Administration unique to Cinryze CINRYZE ™ (C1 Esterase Inhibitor [human])
Slide 8: Prophylaxis vs. Acute Treatment
Prophylaxis vs. Acute Treatment 2009 2010 2011 Prevalent Population i.e. unique individuals in the US who have the disease 11,059 11,154 11,250 Estimate of diagnosed patients 2,544 2,789 3,150 Number of HAE patients who would receive prescription drug therapy 1,628 1,840 2,142 Potential Prophylactic
Slide 9: Patient Access Made Easy
Patient Access Made Easy • Individualized case management • Benefits coverage investigations • Reimbursement assistance • Single point of contact for ongoing support and follow up CINRYZE Solutions ™
Slide 10: Impressive U.S. Launch
Impressive U.S. Launch • Over 400 patients on commercial Cinryze at year end 2009 • Average dosing of 1.7 per week • Significant number of additional patients enrolled into Cinryze Solutions • 218 plans covering at least one patient
Slide 11: Quarterly Cinryze Revenue Growth
Quarterly Cinryze Revenue Growth * Q4 range denotes 2009 Cinryze Net Sales guidance provided on Monday, January 11, 2010
Slide 12: Scale up Progressing to Plan
Scale up Progressing to Plan PCP Industrial Scale Equipment In Place Additional Shift Staffed Personnel Trained Begin Production Finished Product (Q2) Equipment In Place Equipment Validated Conformance Lots Made Pre-Filing FDA Meeting 3-Month Stability FDA Filing (Q3) Finished Product (EOY)
Slide 13: Annual Cinryze Revenue Growth
Annual Cinryze Revenue Growth * 2009 Cinryze Net Sales expected to be near the higher end of the provided range of $90-$95 million * 2010 Cinryze Net Sales Guidance provided January 11, 2010 Estimated Peak Year Sales $350 - Estimated Peak Year Sales $350 - $450M $450M
Slide 14: Vancocin
Vancocin… • FDA advisory panel conducted in 2009 • Panel supported Q1/Q2 sameness requirement • Continued vigilance into the process • Authorized generic ready for release upon approval of 3 party generic product rd
Slide 15: One Way to Consider Generic Impact
One Way to Consider Generic Impact * Assumes greater than 3 generic entrants
Slide 16: Strong Financial Results
Strong Financial Results • Total Products Revenue of $223M • Cinryze Net Sales of $61.3M • Reported Adjusted Net Income of $76M • Increased Cash Position to $289M Financial Results through Q3 2009 Working Capital of $358 of $358 Million * Reconciliation of Adjusted Net Income to GAAP Net Income can
Slide 17: Additional Growth Opportunities
Additional Growth Opportunities • Cinryze as a Platform for Growth • Business Development • Non-toxigenic C. difficile (NTCD)
Slide 18: Broadening the Cinryze Opportunity
Broadening the Cinryze Opportunity • Expanded Territorial and Indication Rights • Orphan drug status in EU • Submitted PIP to EMEA • Plan to submit MAA in second half of 2010 • Analyst Day event planned for March • Global Expansion • Formulation Development • Additional Indications
Slide 19: Adding to the Business
Adding to the Business • Treating serious or life threatening illnesses • High unmet medical needs • Limited commercial infrastructure • Providing both top and bottom line growth We are a Biopharmaceutical Company Focused On: Focused Business Development as Another Engine for Growth
Slide 20: ViroPharma Incorporated: Poised for Growth
ViroPharma Incorporated Poised for Growth Impressive U.S. Launch Cinryze — Platform for Growth Strong Financial Position
Slide 21: ViroPharma Incorporated: Delivering Innovative Treatments for Life-threatening Diseases
ViroPharma Incorporated Delivering Innovative Treatments for Life-threatening Diseases ViroPharma Incorporated Delivering Innovative Treatments for Life-threatening Diseases